Genox Research, Inc.

Japan As Represented by General Director of Agency of National Center for Child Health & Development

Shinji Kagaya

Hirohisa Saito

Ryoichi Hashida

Yuji Sugita

Yoshihiro Yayoi

Differential expression of genes whose expression is different in the activated eosinophils of atopic dermatitis patients was measured by comparative analysis using a gene chip. As a result, the TR3 and TINUR genes, whose expression is significantly elevated in activated eosinophils, were successfully identified. The present inventors discovered that these genes can be used to test for allergic disease and to screen candidate compounds for therapeutic agents for allergic disease.

Methods of testing for allergic diseases, and therapeutic agents for treating same

Genes whose expression differ between that in eosinophils collected from atopic dermatitis patients of the exabartation stage and those of the remission stage were searched via a differential display method. As a result, NOR-1 (MINOR) gene was successfully identified whose expression significantly increased in eosinophils of patients in the remission stage, a stage associated with a decrease of eosinophils. The present inventors discovered that the gene can be successfully employed in testing for allergic diseases and screening for candidate compounds for therapeutic agents.

Growing community of inventors

Tokyo, Japan

Shinji Kagaya